00:00Until recently, patients with Lennox-Gastaut syndrome, a serious encephalopathy of the
00:09development and epilepsy that affects about a million people around the world, did not
00:13have drugs able to offer significant and long-term improvements.
00:17Today, thanks to the free way of AIFA, the reimbursability of fenfluramine, children's
00:22neuropsychiatrists in our country have available a therapeutic option capable of improving
00:27the patient's health prospects.
00:57The mission of the reimbursability of fenfluramine plus the Lennox-Gastaut syndrome agreed by
01:04AIFA is for UCB Italy an important step forward.
01:09Because we are talking about a rare pathology in which the therapeutic outlook is not yet
01:16sufficient to meet the needs of these patients, because they typically speak with resistance.
01:24Fenfluramine is able to reduce epilepsy in a decisive and long-term way and therefore
01:31contribute in a clear way to the quality of life of the patient and his family, but also
01:38to the whole picture of the comorbidities that are accompanied in this pathology.
01:45One of the most complex aspects in the management of Lennox-Gastaut syndrome is the transition
01:50of the patient from the pediatric age to the adult age, a complex moment of transition
01:54that involves the change of the medical team that follows the patient.
01:57There would be a need for institutionalized paths in which the transition follows a path
02:05that certainly cannot be carried out in a single moment, in a single day.
02:10For example, with structured ambulatories that start in adolescence, around 14-15 years old,
02:16the ambulatory provides visits with the presence of the pediatric neuropsychiatrist, the neurologist
02:22and other professional figures such as the psychiatrist, the physiatrist, but also the social assistant,
02:27in some cases the psychologist is very important, and slowly accompany the patient to move
02:33towards the adult environment.
Comments